SCHEMBL407730

SCHEMBL407730

CCCCCCCC/C=C/CCCCCCCCOC(=O)[C@@H](O)CO

nearest known ligand 0.88

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.55
FAAH O00519 3/20 0.52
ALDH1A1 P00352 1/20 0.50
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
PRKCE Q02156 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCD Q05655 1/20 0.49
PRKCA P17252 1/20 0.49
NAAA Q02083 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483499 1.00 DGKA (0.55) DGKAFAAHALDH1A1CNR1CNR2
SCHEMBL5482407 1.00 DGKA (0.55) DGKAFAAHALDH1A1CNR1CNR2
SCHEMBL1768207 1.00 DGKA (0.55) DGKAFAAHALDH1A1CNR1CNR2
SCHEMBL18662301 0.95 ALDH1A1 (0.57) DGKAFAAHALDH1A1CNR1CNR2
Phosphoric Acid SCHEMBL4261864 0.94 LPAR1 (0.51) DGKAFAAH
SCHEMBL23121501 0.90 NAAA (0.59) NAAA
SCHEMBL118318 0.90 NAAA (0.59) NAAA
SCHEMBL114472 0.90 NAAA (0.59) NAAA
SCHEMBL117824 0.90 NAAA (0.59) NAAA
SCHEMBL23467113 0.90 NAAA (0.59) NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2741 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210106538-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2021-04-15 US claimed
EP-3471778-A2 COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS The Regents of The University of Michigan (US) 2019-04-24 EP claimed
WO-2017223085-A2 COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-12-28 WO claimed
US-20150337018-A1 USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS UNIVERSIDAD ANDRES BELLO (CL) 2015-11-26 US claimed
EP-2897632-A2 COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS Universidad Andres Bello (CL) 2015-07-29 EP claimed
WO-2013179264-A2 USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS UNIVERSIDAD ANDRES BELLO (CL) 2013-12-05 WO claimed
US-20040154921-A1 Method for electrophoretic sample separation XZILLION GMBH & CO. KG (DE) 2004-08-12 US claimed
EP-1399734-A2 METHOD FOR ELECTROPHORETIC SAMPLE SEPARATION Xzillion Proteomics GmbH & CO.KG (DE) 2004-03-24 EP claimed
US-20030204077-A1 RNA isolation reagent and methods INVITROGEN CORPORATION 2003-10-30 US claimed
EP-1005479-A4 RNA ISOLATION REAGENT AND METHODS LIFE TECHNOLOGIES INC (US) 2002-12-18 EP claimed
WO-2002099404-A2 METHOD FOR ELECTROPHORETIC SAMPLE SEPARATION XZILLION PROTEOMICS GMBH & CO. KG (DE) 2002-12-12 WO claimed
EP-1005479-A1 RNA ISOLATION REAGENT AND METHODS LIFE TECHNOLOGIES, INC. (US) 2000-06-07 EP claimed
WO-1998045311-A1 RNA ISOLATION REAGENT AND METHODS LIFE TECHNOLOGIES, INC. (US) 1998-10-15 WO claimed
US-20260146252-A1 COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS, INC. (US) 2026-05-28 US disclosed
EP-4744669-A2 APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF Alnylam Pharmaceuticals, Inc. (US) 2026-05-20 EP disclosed
WO-2026101913-A1 SIRNAS TARGETING COMPLEMENT FACTOR H-RELATED (CFHR) GENE TRANSCRIPTS AND METHODS OF USE ALNYLAM PHARMACEUTICALS, INC. (US) 2026-05-15 WO disclosed
WO-1999001579-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL ISIS PHARMACEUTICALS, INC. (US) 1999-01-14 WO disclosed
EP-0287652-A4 SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS. LIFE TECHNOLOGIES INC (US) 1990-01-08 EP disclosed
EP-0287652-A1 SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS. LIFE TECHNOLOGIES INC (US) 1988-10-26 EP disclosed
WO-1988002774-A1 SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS LIFE TECHNOLOGIES, INC. (US) 1988-04-21 WO disclosed